Navigation Links
Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
Date:2/21/2008

GOTHENBURG, Sweden, February 21 /PRNewswire/ -- With two successful international product launches, Swedish biotech firm Cellectricon is entering a new expansion phase. The share issue will strengthen Cellectricon's financial capacity prior to a number of significant product launches in 2008-2009. These products have been developed in close collaboration with leading global pharmaceutical companies to meet the industry's increasing demand for fully automated, highly efficient systems for pre-clinical pharmaceutical development.

"Cellectricon is now entering a new expansion phase, in which the company will soon launch two large-scale systems that will revolutionize drug discovery. This capital will enable us to continue our rapid expansion in the United States, Europe, and Asia," said Dr. Mattias Karlsson, Cellectricon's CEO.

In 2008 Cellectricon will launch the first of their large-scale screening system, Cellaxess(R)HT, which has been developed in close cooperation with one of the world's largest pharmaceutical companies. Cellaxess(R)HT will be the only system on the market that enables large-scale supply of genetic material for cells and is tailor made for high throughput RNAi screening.

About Cellectricon

Cellectricon AB is a Swedish biotech company that is a successful provider of groundbreaking products to the pharmaceutical industry that increase efficiency in pre-clinical pharmaceutical development. Cellectricon has already successfully launched two products onto the market that have been sold to ten of the 12 largest pharmaceutical companies in the world. In 2007 the company increased its revenue by almost 50%. In 2008-2009 launch the high-performance systems Cellaxess(R)HT for RNAi screening and Dynaflow(R)HT for ion channel screening. Cellectricon's forthcoming products address a market that is estimated to be US $1.4 billion by 2010.


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. CardioDynamics Provides 2007 Shareholder Meeting Update
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
8. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Neuralstem Shares Accepted for Trading on Amex(R)
10. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
11. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 Four US Biotech ... today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), ... Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... Trends, market observers are growing more bullish on the ... reforms to free cash held overseas for tax reason ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as ... private label organic services. , The first organic product is Organic 18 Percent Layer ... Dynamite Marketing, which owns the facility. , Catalyst already has received the Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company ... National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month ... technology and is expected to deliver therapeutic levels of olanzapine for a period of ...
(Date:2/24/2017)... FRANCISCO , Feb. 24, 2017 Symic ... is developing a new category of therapeutics, announced today ... of SB-030 in peripheral artery disease. The trial will ... administered single-use therapeutic, in the reduction of restenosis following ... this critical development milestone for SB-030," said Nathan ...
Breaking Biology Technology:
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
Breaking Biology News(10 mins):